Hexarelin

Lipid Metabolism

Dyslipidemia is an independent risk factor for diabetes even in non-obese individuals. Research in insulin-resistant MKR mice demonstrated that hexarelin corrects lipid metabolic aberrations while simultaneously lowering blood sugar and improving insulin sensitivity (Mosa et al., 2017). These findings suggest hexarelin may offer an alternative approach to managing dyslipidemia in the setting of metabolic syndrome.

Skeletal Muscle Protection

Hexarelin protects skeletal muscle from mitochondrial damage and calcium dysregulation in cachexia models. In cisplatin-induced cachexia in rats, hexarelin preserved mitochondrial DNA content, maintained muscle protein levels, and protected myosin heavy chain expression (Sirago et al., 2017). The peptide also prevents the calcium homeostasis disruption caused by chemotherapy that leads to muscle wasting (Conte et al., 2017).

Ongoing & Future Research

Active and recent clinical investigations involving hexarelin and its cardioprotective mechanisms include:

• NCT00263952: Growth hormone secretagogues and cardiac function -- evaluating hemodynamic effects of GHSR agonists in patients with heart failure
• NCT01444703: Ghrelin receptor agonists in cachexia and muscle wasting -- examining preservation of lean body mass during cancer treatment
• NCT00093613: Ghrelin and ghrelin mimetics on body composition in wasting conditions
• NCT02058264: Investigation of ghrelin pathway modulation in cardiac rehabilitation and post-MI recovery

Key areas of active preclinical investigation:

• Cardioprotection mechanisms: Continued elucidation of CD36 signaling cascades, including PTEN/Akt modulation, calcium channel regulation, and mitochondrial protection in ischemia/reperfusion injury
• Skeletal muscle protection in cancer cachexia: Expanding from cisplatin models to other chemotherapy agents and tumor-driven cachexia, with focus on the JNK and PI3K/AKT pathways identified by Gortan Cappellari et al. (2023)
• Diabetic cardiomyopathy: Ongoing research into hexarelin's ability to protect against diabetic cardiac dysfunction through calcium and potassium channel modulation, with potential for clinical translation (Zhang et al., 2018)
• Oral formulation development: Optimization of oral hexarelin delivery for sustained CD36-mediated cardioprotection, leveraging the finding that oral dosing provides meaningful cardiac effects (Mao et al., 2014)

Cardioprotection

Hexarelin directly protects cardiomyocytes from ischemia/reperfusion injury by binding CD36 and GHSR receptors, preventing apoptosis. Studies in mice showed improved cardiac function, increased cardiomyocyte survival, and decreased malondialdehyde production following myocardial infarction (Huang et al., 2017; Mao et al., 2013).

Research in rat heart failure models demonstrated that hexarelin reduces oxidative stress and prevents myocardial remodeling through PTEN upregulation and Akt downregulation (Agbo et al., 2019). Chronic administration attenuates cardiac fibrosis in spontaneously hypertensive rats (Xu et al., 2012), and a single oral dose was shown to provide sustained cardioprotection after myocardial infarction (Mao et al., 2014). Hexarelin shifts autonomic balance from sympathetic to parasympathetic dominance, further reducing long-term cardiac stress and medication requirements (McDonald et al., 2018).

Because the cardioprotective mechanism is not specific to ischemic damage, researchers have explored hexarelin in diabetic cardiomyopathy. Studies in streptozotocin-induced diabetic rats found that hexarelin improved cardiac function by modulating calcium and potassium handling in cardiomyocytes (Zhang et al., 2018; Ma et al., 2012).

Comparison to Related Compounds

Hexarelin's distinguishing feature is its strong CD36 binding, which confers direct cardioprotective effects independent of GH release. This separates it from GHRP-2 and ipamorelin, which lack CD36 affinity and provide cardiac benefits only indirectly through GH/IGF-1 pathways. While GHRP-6 also binds CD36, hexarelin's CD36 affinity is stronger and its cardioprotective effects are more extensively documented (Mao et al., 2013).

Compared to endogenous ghrelin, hexarelin is resistant to enzymatic degradation (particularly by butyrylcholinesterase and other serine proteases) due to its D-amino acid substitutions, giving it a substantially longer half-life. Unlike full-length growth hormone, hexarelin provides cardioprotection through a receptor pathway (CD36) that GH cannot access, making hexarelin's cardiac effects complementary to, rather than redundant with, GH therapy (Zhang et al., 2023).